Literature DB >> 22155900

HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B.

Beom Kyung Kim1, Peter A Revill, Sang Hoon Ahn.   

Abstract

Although chronic HBV infection is the leading cause of chronic liver disease and death worldwide, there are substantial differences in its clinical courses regarding prevalence, mode of transmission, characteristics of each phase, responses to antiviral therapy, and development of cirrhosis and hepatocellular carcinoma, according to geographical areas (Asia versus Western Europe and North America versus Africa). Furthermore, the clinical course in infected individuals depends on a complex interplay among various factors including viral, host, environmental and other factors. Recently, understanding of molecular characteristics of the prevailing HBV genotypes, frequently accompanied mutations and their clinical implications might explain these geographical differences more pertinently. Hence, in this article, we review the global epidemiology and the natural history of HBV infection, with emphasis on summarizing the different HBV genotypes according to regions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155900     DOI: 10.3851/IMP1982

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  48 in total

1.  Genotyping of hepatitis B virus isolates from Lahaul and Spiti district in Himachal Pradesh, India.

Authors:  Brij Sharma; Harshita Katiyar; Deepesh Barall; Neetu Sharma; Shikha Agnihotry; Amit Goel; Rakesh Aggarwal
Journal:  Indian J Gastroenterol       Date:  2018-06-01

Review 2.  Global strategies are required to cure and eliminate HBV infection.

Authors:  Peter Revill; Barbara Testoni; Stephen Locarnini; Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

3.  New perspectives on the hepatitis B virus life cycle in the human liver.

Authors:  Peter A Revill; Stephen A Locarnini
Journal:  J Clin Invest       Date:  2016-02-22       Impact factor: 14.808

Review 4.  Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.

Authors:  Shiv K Sarin; Manoj Kumar; Mohammed Eslam; Jacob George; Mamun Al Mahtab; Sheikh M Fazle Akbar; Jidong Jia; Qiuju Tian; Rakesh Aggarwal; David H Muljono; Masao Omata; Yoshihiko Ooka; Kwang-Hyub Han; Hye Won Lee; Wasim Jafri; Amna S Butt; Chern H Chong; Seng G Lim; Raoh-Fang Pwu; Ding-Shinn Chen
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-12-15

Review 5.  Potential mechanisms of hepatitis B virus induced liver injury.

Authors:  Mohd Suhail; Hany Abdel-Hafiz; Ashraf Ali; Kaneez Fatima; Ghazi A Damanhouri; Esam Azhar; Adeel Ga Chaudhary; Ishtiaq Qadri
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 6.  Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir.

Authors:  Ezequiel Ridruejo
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 7.  Management of antiviral drug resistance in chronic hepatitis B.

Authors:  Ki Bae Bang; Hong Joo Kim
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

8.  Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.

Authors:  Hana Park; Jun Yong Park; Seung Up Kim; Do Young Kim; Kwang-Hyub Han; Chae Yoon Chon; Sang Hoon Ahn
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

9.  Hepatitis B treatment eligibility in West Africa: Uncertainties and need for prospective cohort studies.

Authors:  Antoine Jaquet; Marcellin Nouaman; Judicaël Tine; Aristophane Tanon; Camille Anoma; André Inwoley; Alain Attia; Didier K Ekouevi; Moussa Seydi; François Dabis; Gilles Wandeler
Journal:  Liver Int       Date:  2017-06-22       Impact factor: 5.828

Review 10.  The evolution and clinical impact of hepatitis B virus genome diversity.

Authors:  Peter A Revill; Thomas Tu; Hans J Netter; Lilly K W Yuen; Stephen A Locarnini; Margaret Littlejohn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-05-28       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.